Sanofi SNY announced that the FDA has granted a fast-track designation to its mRNA vaccine candidate for the prevention of ...

Jean-François Toussaint, Sanofi's global head of vaccines R&D, speaking at a conference at the company's site in Lyon last ...

US FDA grants fast track designation to Sanofi’s mRNA vaccine candidate for prevention of chlamydia infection: Paris Friday, March 28, 2025, 12:00 Hrs [IST] The US Food and Drug ...

The Food and Drug Administration (FDA) has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

The US Food and Drug Administration (FDA) today approved the first at-home, over-the-counter test for chlamydia, gonorrhea, and trichomoniasis.

Chlamydia vaccine candidate granted fast track designation by the US FDAChlamydia infection can contribute to pelvic inflammatory diseases in ...

Paris: Sanofi has received the US Food and Drug Administration (USFDA) fast-track designation for its mRNA vaccine candidate ...

Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.

The FDA has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

This decision underscores the need for a preventative measure against the chlamydia, which affects millions worldwide.

Sanofi’s vaccine is designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis, which is responsible for the most common sexually ...